Bristol-Myers Squibb's third-quarter results exceeded expectations, raising revenue expectations for 2026, and the pre-market stock price rose 2.2%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.